secondary hyperparathyroidism


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to secondary hyperparathyroidism: renal secondary hyperparathyroidism

sec·on·dar·y hy·per·par·a·thy·roid·ism

hyperparathyroidism that arises as a result of disordered metabolism producing hypocalcemia, as in chronic uremia due to renal disease, malabsorption, rickets, or osteomalacia; associated with hyperplasia of the parathyroid glands.

secondary hyperparathyroidism

Endocrinology ↑ Parathyroid activity with overproduction of PTH due to parathyroid hyperplasia in response to an extraparathyroid defect that results in ↓ Ca2+ Etiology Rickets, vitamin D deficiency, chronic renal failure Organs affected Bone, GI tract, kidneys, CNS, muscle

secondary hyperparathyroidism

Excessive levels of parathyroid hormone (PTH) released in response to a low serum calcium, or a high serum phosphate level. It may be due to vitamin D deficiency or chronic kidney disease.

sec·on·dar·y hy·per·par·a·thy·roid·ism

(sekŏn-dar-ē hīpĕr-pară-thīroyd-izm)
Disorder that occurs as a complication of renal disease that affects all four parathyroid glands.
References in periodicals archive ?
Vitamin D deficiency: secondary hyperparathyroidism and osteoporosis
Cinacalcet HCl is approved for the treatment of secondary hyperparathyroidism, and an increasing number of studies suggest that cinacalcet HCl is also effective for treatment of primary hyperparathyroidism (10, 11).
Cinacalcet, which was approved by the Food and Drug Administration in March 2004, is the first agent in its class that treats secondary hyperparathyroidism by increasing the sensitivity of calcium-sensing receptors.
Irrespective of the cause, the high level of PTH observed with primary or secondary hyperparathyroidism increases osteoclast activity, which eventually leads to osteodystrophy.
The clinical utility of these first-generation IRMAs in the diagnosis of primary hyperparathyroidism and in monitoring the severity of secondary hyperparathyroidism in ESRD is well established.
Intraoperative parathyroid hormone monitoring during parathyroidectomy for secondary hyperparathyroidism.
was approved in June 1999 for treatment of secondary hyperparathyroidism in chronic dialysis patients.
Phase 2 Clinical Trial of KAI-4169 for Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Anticipated to Complete by Year-End 2011
July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.
Abbott (NYSE: ABT)today announced the publication of a Phase 4 clinical trial comparing the efficacy of Zemplar against cinacalcet plus low-dose vitamin D in treating secondary hyperparathyroidism (SHPT) in patients on kidney dialysis (hemodialysis).
In studies, approximately 12%-18% of Paget's disease patients have elevated levels of parathyroid hormone (PTH), most of which represent secondary hyperparathyroidism.
Mimpara is now authorized in the EU for the treatment of secondary hyperparathyroidism (SHPT) in patients with CKD on dialysis as well as for the treatment of elevated calcium levels in patients with cancer of the parathyroid gland.

Full browser ?